Loading market data...
Tue, 21 Jul 2026
01:45:42 am
Tue, 21 Jul 2026
01:45:42 am
Synopsis
Pharma stocks including Cipla, Ajanta Pharma, Torrent Pharmaceuticals and Alkem Laboratories gained despite a weak stock market. Nifty Pharma index climbed over 1.6% as investors turned defensive amid global uncertainty.
Pharma stocks outperformed the broader Indian equity market on Monday, with buying interest across the healthcare sector lifting the Nifty Pharma index by more than 1.6%, even as benchmark indices remained under pressure due to weak global cues and rising geopolitical tensions.
The sector-wide rally came as investors shifted towards relatively defensive sectors amid concerns over the escalating US-Iran conflict, higher crude oil prices and weakness across global equity markets. While the BSE Sensex fell over 670 points and the Nifty 50 traded lower during the session, several pharmaceutical stocks registered strong gains.
Large-cap names including Torrent Pharmaceuticals, Mankind Pharma, Cipla, Divi's Laboratories, Laurus Labs, Alkem Laboratories, Ajanta Pharma, Aurobindo Pharma and Zydus Lifesciences advanced, while several mid-cap and small-cap pharmaceutical companies posted even sharper gains.
The Nifty Pharma index climbed around 1.65%, significantly outperforming the benchmark indices, as investors rotated into healthcare stocks during a broader market sell-off.
At the time of writing, the BSE Sensex was down 671.29 points (0.86%) at 77,480.16, while the NSE Nifty 50 declined 169.40 points (0.70%) to 24,164.75.
| Index | Performance |
|---|---|
| Nifty Pharma | +1.65% |
| BSE Sensex | 77,480.16 (-671.29 points / -0.86%) |
| Nifty 50 | 24,164.75 (-169.40 points / -0.70%) |
The divergence highlighted investors' preference for sectors generally considered more resilient during periods of market volatility.
Among the constituents of the Nifty Pharma index, Torrent Pharmaceuticals and Mankind Pharma emerged as the top gainers, with both stocks rising more than 3% during intraday trade.
Other major pharmaceutical companies also witnessed healthy buying interest.
| Company | Intraday Gain |
|---|---|
| Torrent Pharmaceuticals | More than 3% |
| Mankind Pharma | More than 3% |
| Cipla | Over 2% |
| Divi's Laboratories | Over 2% |
| Laurus Labs | Over 2% |
| Alkem Laboratories | Over 2% |
| Sai Life Sciences | Over 2% |
| Ajanta Pharma | Over 1% |
| Aurobindo Pharma | Over 1% |
| Zydus Lifesciences | Over 1% |
The gains reflected broad-based buying across both established pharmaceutical manufacturers and specialty healthcare companies.
The positive momentum was not limited to large-cap pharmaceutical companies.
Several mid-cap and small-cap healthcare stocks registered stronger gains, with some counters advancing as much as 7% during the trading session.
| Company | Gain |
|---|---|
| RPG Life Sciences | Up to 7% |
| Thyrocare Technologies | Up to 7% |
| Hester Biosciences | Up to 7% |
| Onesource Specialty Pharma | Up to 7% |
| Neuland Laboratories | Up to 7% |
The rally indicated widespread participation across the pharmaceutical sector rather than being concentrated in a few large-cap names.
Outside the pharmaceutical index, Tatva Chintan Pharma Chem also remained in focus after reporting strong Q1 FY27 results.
The stock surged nearly 20% to touch a fresh 52-week high of ₹1,714.10 on the BSE following its quarterly earnings announcement. The company reported a sharp improvement in revenue, profitability and operating margins while also announcing a ₹200 crore capacity expansion at its Dahej manufacturing facility.
The pharmaceutical sector benefited from a defensive investment strategy as investors sought relatively stable businesses amid growing uncertainty in global markets.
Escalating tensions surrounding the US-Iran conflict and the resulting increase in crude oil prices weighed on investor sentiment, leading to broad-based selling in benchmark indices. Healthcare and pharmaceutical companies are often viewed as defensive investments because demand for medicines and healthcare products tends to remain relatively stable across economic cycles.
The sector also continued to receive support from company-specific developments, including strong quarterly earnings, capacity expansion announcements and improving operational performance reported by several pharmaceutical and specialty chemical companies during the earnings season.
India's pharmaceutical industry is one of the largest producers of generic medicines globally, with companies manufacturing products across therapeutic segments including chronic therapies, vaccines, biosimilars, active pharmaceutical ingredients (APIs), specialty formulations and contract development and manufacturing services (CDMO). The sector continues to benefit from export demand, domestic healthcare growth and increasing investments in research, manufacturing capacity and specialty products.
Pharma stocks gained as investors shifted towards defensive sectors amid weakness in the broader market caused by geopolitical tensions, higher crude oil prices and negative global market sentiment. The Nifty Pharma index rose more than 1.6% while benchmark indices traded lower.
Torrent Pharmaceuticals and Mankind Pharma led the gains among Nifty Pharma constituents with rallies of more than 3%. Cipla, Divi's Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences also gained over 2%.
The pharmaceutical sector is generally considered defensive because demand for medicines, healthcare services and essential drugs remains relatively stable regardless of economic conditions, making earnings less sensitive to economic slowdowns than many other industries.
RPG Life Sciences, Thyrocare Technologies, Hester Biosciences, Onesource Specialty Pharma and Neuland Laboratories were among the top-performing mid-cap and small-cap healthcare stocks, with gains of up to 7% during the trading session.
Tatva Chintan Pharma Chem surged nearly 20% after reporting strong Q1 FY27 results, with revenue rising 43%, net profit more than doubling and EBITDA increasing 86.6%. The company also announced a ₹200 crore capacity expansion at its Dahej manufacturing facility
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
D.P. Abhushan reported a 77% rise in Q1 FY27 net profit to ₹644.95 million as revenue crossed ₹8.52 billion.
Can Fin Homes reported a 20% rise in Q1 FY27 net profit to ₹268 crore, while net interest income increased 18%.
Shyam Metalics & Energy reported strong Q1 FY27 results with net profit rising 21% to ₹351 crore and revenue increasing 23% to ₹5,455 crore.
Paytm parent One 97 Communications is expected to announce its first-ever bonus issue along with Q1 FY27 results today.
A small-cap multibagger has fixed tomorrow as the record date for its upcoming stock split. Today is the final opportunity for eligible investors to...
